Logo En IconLogo Mark IconIcelandic Intellectual Property Office

SPC502

Sjálfgena and-CD19-umleiddar CD3+ frumur (brexucabtagene autoleucel) / Autologous anti-CD19-transduced CD3+ cells (brexucabtagene autoleucel)

  • Status:
    Umsókn
  • Application date:
    26.2.2025
  • Application published:
    15.3.2025
  • Medicine name:
    Tecartus
  • Medicine for children:
    No

Timeline

Today
26.2.2025Application
15.3.2025Publication

Marketing license

  • IS authorization number:
    EU/1/20/1492
  • Date:
    8.1.2021
  • Foreign authorization number:
    EU/1/20/1492
  • Date:
    14.12.2020

Owner

  • Name:
    The United States of America, as Represented by The Secretary, Department of Health and Human Services
  • Address:
    Office of Technology Transfer National Institutes of Health 6701 Rockledge Drive Suite 700, MSC 7788, Bethesda, Maryland 20892-7788 US
  • Name:
    Kite Pharma, Inc.
  • Address:
    2400 Broadway, Santa Monica, CA 90404 US

Agent

  • Name:
    Árnason Faktor ehf.
  • Address:
    Guðríðarstíg 2-4, 113 Reykjavík

Patent

Upload documents